Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADM-Dex-ScFv-SA3
- Development stage
- Preclinical
- Lead developer
- Central South University
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**ADM-Dex-ScFv-SA3** is an experimental, hepatocellular carcinoma-targeted immunoconjugate comprising the anti-hepatoma human single-chain variable fragment ScFv-SA3, oxidized dextran T10 linker, and the anthracycline cytotoxic payload adriamycin. The ScFv-SA3 component selectively binds HepG2 hepatocellular carcinoma cells, enabling preferential delivery of the doxorubicin payload. In cell-based assays and HepG2 xenograft mouse models, the conjugate inhibited tumor-cell proliferation and colony formation, suppressed tumor growth, and prolonged survival. It is a preclinical candidate reported by investigators at Central South University for hepatocellular carcinoma.
- Other names
- ADM-Dex-ScFv-SA3ADM-Dex-ScFv-SA-3ADM-Dex-ScFv-SA 3
02
Targets
TOP2A (DNA topoisomerase II)HTA (Hepatoma-associated antigen HTA)DNA
Beyond the preview
Go deeper on ADM-Dex-ScFv-SA3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADM-Dex-ScFv-SA3.